Drug Trial News

RSS
BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante vaccine increases median survival of resected pancreatic cancer patients

4 Mar 2011
Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

4 Mar 2011
Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

4 Mar 2011
Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

4 Mar 2011
Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

4 Mar 2011
Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

3 Mar 2011
Clinical trials in Australia take too long– need uniform standards: Report

Clinical trials in Australia take too long– need uniform standards: Report

3 Mar 2011
Glenmark Generics granted final FDA approval for generic Xyzal ANDA

Glenmark Generics granted final FDA approval for generic Xyzal ANDA

3 Mar 2011
Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

3 Mar 2011
Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

3 Mar 2011
Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

3 Mar 2011
Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

3 Mar 2011
Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

3 Mar 2011
Lixte receives $244,479.25 U.S. government grant for QTDP program

Lixte receives $244,479.25 U.S. government grant for QTDP program

3 Mar 2011
Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

3 Mar 2011
Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

3 Mar 2011
EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

3 Mar 2011
Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

3 Mar 2011
FDA accepts Handa's generic DEXILANT ANDA for review

FDA accepts Handa's generic DEXILANT ANDA for review

2 Mar 2011
Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

2 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback